Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 5Neoplasm Metastasis 4Sarcoma 3Rectal Neoplasms 3Pancreatic Neoplasms 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Lymphoma 2Ovarian Neoplasms 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Insulin-Like Growth Factor I, Resistance To 1Hodgkin Disease 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoid Tumor 1Adenocarcinoma 1

Interventions

ganitumab 3Paclitaxel 23-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 2tislelizumab 1teprotumumab 1dalotuzumab 1conatumumab 1cixutumumab 1Sorafenib 1Receptor Protein-Tyrosine Kinases 1Lapatinib 1Istiratumab 1Cisplatin 1Carboplatin 1Capecitabine 1BIIB022 1Antibodies, Monoclonal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Insulin-Like Growth Factor I, Resistance To × conatumumab × Clear all
NCT00630552 2024-10-17

QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer

NantCell, Inc.

Phase 1/2 Completed
138 enrolled 19 charts
Gastrointestinal

Insulin-Like Growth Factor I, Resistance To, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡